scholarly journals Thoracoscopic sympathectomy for palmar hyperhidrosis and Raynaud's phenomenon of the upper limb and excessive facial blushing: a five year experience

2002 ◽  
Vol 78 (925) ◽  
pp. 682-684 ◽  
Author(s):  
Y S Rajesh
Keyword(s):  
Upper Limb ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon ◽  
Palmar Hyperhidrosis ◽  
Thoracoscopic Sympathectomy ◽  
Facial Blushing

The complementary effects of galvanic current electrical stimulation associated with conservative treatment to increase vasodilation in patients with Raynaud’s phenomenon: a randomized trial

2020 ◽  
Vol 34 (5) ◽  
pp. 595-606 ◽  
Author(s):  
Rosa María Tapia-Haro ◽  
Mª Carmen García-Ríos ◽  
Sonia Toledano-Moreno ◽  
Antonio Casas-Barragán ◽  
Adelaida Mª Castro-Sánchez ◽  
...  
Keyword(s):  
Blood Flow ◽  
Electrical Stimulation ◽  
Conservative Treatment ◽  
Upper Limb ◽  
Central Sensitization ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon ◽  
Artery Blood Flow ◽  
Galvanic Current ◽  
Temperature Recovery

Objective: To analyze the effectiveness of an electrotherapy intervention with galvanic current on symptoms associated with Raynaud’s phenomenon. Design: Single-blind randomized controlled trial, parallel design (1:1 ratio) and intention-to-treat analysis. Setting: Virgen de las Nieves Hospital, Granada, Spain. Subjects: Thirty-four participants with Raynaud’s phenomenon, with a mean (SD) age of 43.43 (17.62) years. Interventions: The patients were randomly assigned to a control group with conservative treatment (anti-inflammatory, vasodilatory and analgesic drugs) or an intervention group that received conservative treatment and vasodilatory electrical stimulation during seven weeks, three times/week for a total of 20 sessions. Main measures: The primary outcome was the number of attacks. Secondary outcomes were pain, peripheral blow flow, oxygen saturation, upper limb disability, central sensitization, pain catastrophizing and temperature recovery. All outcomes were assessed at baseline, posttreatment and at two months of follow-up. Results: The galvanic current electrotherapy group showed significantly greater improvements in the number of attacks (mean difference = 26.3, 95% confidence interval (CI) = 14.4 to 38.3), pre-cold stress pain (95% CI = 0.6 to 2.4), radial artery blood flow (95% CI = −7.8 ⩾  x ⩽ 1.3), ulnar artery blood flow (95% CI = −8.63 to 0.60), oxygen saturation (95% CI = −1.7 ⩾  x ⩽ −0.29), upper limb disability (95% CI = 1.1 to 22.3), central sensitization (95% CI = 6.7 to 18.2) and temperature recovery (95% CI = −5.7 ⩾  x ⩽ −0.32) than the conservative treatment group. Conclusion: This study suggests that a complementary treatment with galvanic current in combination to conservative approach is superior to conservative applied as isolate, in reducing the clinical manifestations and disability in Raynaud’s phenomenon.

t-PA, PAI, and Protein C Before and After Vascular Occlusion of the Upper Limb in Patients with Raynaud's Phenomenon

Angiology ◽  
1991 ◽  
Vol 42 (3) ◽  
pp. 231-238 ◽  
Author(s):  
Claudio Cimminiello ◽  
Massimo Milani ◽  
Tiziano Uberti ◽  
Guido Arpaia ◽  
Adele Motta ◽  
...  
Keyword(s):  
Upper Limb ◽  
Protein C ◽  
Raynaud’S Phenomenon ◽  
Vascular Occlusion ◽  
Raynaud's Phenomenon ◽  
Before And After

Nerve conduction velocity study of the upper limb in Raynaud's phenomenon

2000 ◽  
Vol 19 (5) ◽  
pp. 165-169 ◽  
Author(s):  
M. Mondelli ◽  
C. Romano ◽  
R. De Stefano ◽  
R. Cioni
Keyword(s):  
Conduction Velocity ◽  
Upper Limb ◽  
Nerve Conduction ◽  
Nerve Conduction Velocity ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon

scholarly journals TO THE QUESTION OF THE UPPER LIMB DESYMPATHISATION IN RAYNAUD’S PHENOMENON

2018 ◽  
Vol 20 (1) ◽  
pp. 113-119
Author(s):  
Rakhimdzhon Rakhmatullaev ◽  
◽  
Bahodur Ulmasovich Abduvakhidov ◽  
Orifdzhon Negmatovich Pulatov ◽  
Fakhriddin Shamsiddinovich Rashidov ◽  
...  
Keyword(s):  
Upper Limb ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon

Ascorbic Acid does not Improve Endothelium-Dependent Flow-mediated Dilatation of the Brachial Artery in Patients with Raynaud’s Phenomenon Secondary to Systemic Sclerosis

2003 ◽  
Vol 73 (1) ◽  
pp. 3-7 ◽  
Author(s):  
M. E. Mavrikakis ◽  
J. P. Lekakis ◽  
M. Papamichael ◽  
K. S. Stamatelopoulos ◽  
Ch. C. Kostopoulos ◽  
...  
Keyword(s):  
Ascorbic Acid ◽  
Smooth Muscle ◽  
Systemic Sclerosis ◽  
Endothelial Dysfunction ◽  
Brachial Artery ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon ◽  
Water Soluble ◽  
Placebo Administration ◽  
Flow Mediated Dilatation

Previous studies have shown that patients with Raynaud’s phenomenon secondary to systemic sclerosis present abnormal endothelial function; the mechanisms responsible for the endothelial dysfunction are unknown but increased vascular oxidative stress could be a possible cause. The hypothesis that a potent water-soluble antioxidant can reverse endothelial dysfunction in these patients was tested in the present study. We examined 11 female patients with Raynaud’s phenomenon secondary to systemic sclerosis and ten healthy control women by ultrasound imaging of the brachial artery to assess flow-mediated (endothelium-dependent) and nitrate-induced (endothelium-independent) vasodilatation. Flow-mediated dilatation and nitrate-induced dilatation were significantly reduced in patients with Raynaud’s phenomenon, indicating abnormal endothelial and smooth muscle cell function. Patients with Raynaud’s phenomenon entered a double-blind, randomized, crossover placebo-controlled trial and received orally 2 g of ascorbic acid or placebo; vascular studies were repeated two hours after ascorbic acid or placebo administration. Flow-mediated dilatation did not improve after ascorbic acid (1.6 ± 2.2% to 2.2 ± 2.5%, ns) or placebo administration (1.2 ± 1,9% to 1.7 ± 1.4%, ns); also nitrate-induced dilatation was similar after ascorbic acid or placebo (16 ± 7.4% vs 17 ± 8%, ns), suggesting no effect of ascorbic acid on endothelial and vascular smooth muscle function. In conclusion, ascorbic acid does not reverse endothelial vasomotor dysfunction in the brachial circulation of patients with Raynaud’s phenomenon secondary to systemic sclerosis. The use of different antioxidants or different dosing of ascorbic acid may be required to show a beneficial effect on endothelial vasodilator function.

The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud’s phenomenon secondary to collagenosis

VASA ◽  
2005 ◽  
Vol 34 (4) ◽  
pp. 243-249 ◽  
Author(s):  
Drinda ◽  
Neumann ◽  
Pöhlmann ◽  
Vogelsang ◽  
Stein ◽  
...  
Keyword(s):  
Laser Doppler Flowmetry ◽  
Raynaud’S Phenomenon ◽  
Raynaud's Phenomenon ◽  
Plasma Viscosity ◽  
Laser Doppler ◽  
Erythrocyte Aggregation ◽  
Control Group ◽  
Long Term Effects ◽  
Doppler Flowmetry

Background: Prostanoids are used in the treatment of Raynaud’s phenomenon and acral perfusion disorders secondary to collagenosis. In subjective terms, intravenous administration of these agents produces success in more than 50% of patients. The therapeutic outcome of clinical administration of alprostadil or iloprost may vary from individual to individual. Patients and methods: The following variables were analysed in a cross-over study in 27 patients with collagenosis and Raynaud’s phenomenon: plasma viscosity and erythrocyte aggregation (rheological variables), partial pressure of oxygen and laser Doppler flowmetry in the finger region, and lymphocyte phenotyping and interleukin (IL) determinations (immunological variables). Results: Laser Doppler flowmetry revealed significant differences between patients with secondary Raynaud’s phenomenon and a control group of 25 healthy subjects. Laser Doppler readings did not change significantly as a result of the treatments. Therapy with iloprost produced a reduction in IL-1beta, L-selectin (CD 62 L) and IL-6. Conclusion: The change in immunological variables due to iloprost may explain the long-term effects of prostaglandins in the treatment of Raynaud’s phenomenon. From our results it is not possible to infer any preference for iloprost or alprostadil.

Sign in / Sign up

Export Citation Format

Share Document